Customize your JAMA Network experience by selecting one or more topics from the list below.
Fu and colleagues investigate whether oral administration of fingolimod, a Food and Drug Administration–approved sphingosine 1–phosphate receptor modulator for multiple sclerosis, is safe and effective in alleviating perihematomal edema (PHE) and neurologic deficits in patients with intracerebral hemorrhage (ICH). They included 23 patients with primary supratentorial ICH with hematomal volume of 5 to 30 mL. They report that in patients with small- to moderate-sized deep primary supratentorial ICH, administration of oral fingolimod within 72 hours of disease onset was safe, reduced PHE, attenuated neurologic deficits, and promoted recovery. Editorial perspective is provided by Kevin N. Sheth, MD, and Jonathan Rosand, MD, MSc.
Highlights. JAMA Neurol. 2014;71(9):1069. doi:https://doi.org/10.1001/jamaneurol.2013.4166
Create a personal account or sign in to: